Indian Equities
Independent
Equity Research
on Indian Markets.
Institutional-grade analysis on Indian listed companies and sectors. Mid-Cap focus. Data-anchored.
Initiating Coverage
Symbiotec Pharmalab Ltd.
NSE: SYMBIOTEC · Steroid APIs + CDMO · 18 Oct 2026
Rating
ACCUMULATE
12M TP
₹1,510
Upside
+18%
PAT CAGR
31.7%
Global leader in steroid APIs — 80%+ volume share in hydrocortisone, testosterone, and methylprednisolone. Adding biotech CDMO fermentation and complex injectables to compound growth runway.
Open Report →
Sector Primer
The Indian Pharma Landscape
First-Principles · 30 Sep 2026
Patent Cliff
$300B+
India US Share
47%
BIOSECURE Opp.
$1.4B/yr
US Generics
89% Rx
$300B+ in branded drug patents expire by 2030. India supplies 47% of US generic prescriptions. BIOSECURE Act shifts CDMO contracts from China.
Open Primer →
Initiating Coverage
Transrail Lighting Ltd.
NSE: TRANSRAIL · T&D EPC · 9 Mar 2026
Rating
BUY
DCF TP
₹659
Upside
+37%
Order Book
₹18,216 Cr
Integrated tower + conductor manufacturing captures margin peers cede to suppliers. International revenue at 55% insulates from PGCIL award cycle.
Open Report →
Coverage Universe
Research across India's
high-conviction sectors.
Focused on mid-cap Indian equities where institutional coverage is thin and information edge matters.
Power & T&D
Transformer manufacturers, EPC players, transmission infrastructure. Value chain coverage from SME to listed majors.
Defence & Aerospace
Indigenisation beneficiaries, precision engineering, DRDO-linked supply chains and export-oriented defence players.
Banks & NBFCs
Small finance banks, MFI-NBFCs, fintech lenders. Focus on underserved credit segments and financial inclusion plays.
Capital Goods & Engineering
Industrial machinery, EPC companies, automation and robotics. Beneficiaries of India's manufacturing capex cycle.
Renewables
Solar EPC, C&I renewable developers, BESS integrators. Tracking India's energy transition capex and grid-scale storage buildout.
Pharma & CDMO
API manufacturers, CDMO plays, generics formulators. First-principles approach to the patent cliff, complexity moat, and India's contract manufacturing opportunity.
Selected Research
Recent coverage.
Published Research
Pharma · Steroid APIs
Symbiotec Pharmalab Ltd.: Initiating CoverageNSE: SYMBIOTEC · ACCUMULATE · 12M TP ₹1,510 · +18% upside · 45x FY29E EPS · 18 Oct 2026
Valuation Model
Symbiotec Pharmalab Ltd.: Financial ModelNSE: SYMBIOTEC · 3-Statement + Valuation · Bear ₹521 / Base ₹1,512 / Bull ₹2,694 · 22 Oct 2026
Pharma & CDMO
The Indian Pharma Landscape: A First-Principles Primer12-page sector primer · Patent cliff · CDMO value chain · Complexity as moat · 30 September 2026
Valuation Model
Transrail Lighting Ltd.: DCF ModelNSE: TRANSRAIL · Bear/Base/Bull · WACC 14.37% · TGR 4.5% · Base TP ₹659 · +37% upside · Oct 2026
Valuation Model
Rajesh Power Services Ltd.: DCF ModelNSE: RPSL · Bear/Base/Bull · WACC 14.86% · Base TP ₹1,668 · +92% upside · March 2026
If you read research
rather than just consume it.
Portfolio managers, allocators, and founders of companies in coverage — if you want to discuss a thesis, push back on a call, or explore a research collaboration, reach out directly.